Our primary market focus is in the cardiovascular area, particularly in patients with one or more conditions characterized by ischemia. Patients with ischemia may receive treatment by vascular surgery or other methods to open or bypass obstructed blood vessels. Often, however, patients have such extensive obstruction, or obstruction in blood vessels that are so difficult to reach, that these techniques are not available.

Preclinical research and our clinical trials to date suggest that ALDH^br cells sorted from bone marrow may promote the repair of ischemic tissue, which has encouraged us to focus on ischemic conditions as our primary market. Our product candidates are intended to address critical limb ischemia, ischemic heart failure and postacute ischemic stroke, each of which have few or no FDA-approved treatments.